Microcyclophotocoagulation in Glaucoma Treatment: A Medium-Term Follow-Up Study.

Bartłomiej Bolek Adam Wylęgała Edward Wylegala

Published in: Journal of clinical medicine (2023)

The µCPC is well tolerated and safe for reducing IOP in glaucoma patients in medium-term follow-up; however, success is moderate. Randomized, larger studies are needed to confirm the obtained results.

Keyphrases

preterm infants
ejection fraction
newly diagnosed
open label
prognostic factors
double blind
gestational age
optic nerve
placebo controlled
randomized controlled trial
patient reported outcomes
phase ii
preterm birth